CME in the 13F filings
Cme Group Inc · CUSIP 12572Q105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 46
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 31 listed it in both
- Shares listed
- 41,834,563
- combined, among listed positions
- Reported value
- $11.4bn
- combined, at the quarter end
Among the 92 comparable managers: 20 buyers (opened or added shares) and 26 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -3,145,558.
Managers listing CME in Q4 2025
46 of 46 holders
Largest increases and reductions, by shares
Increases
- Citadel Advisors LLCexisting position · 1,297,647 shares now+938,015
- Janus Henderson Group Ltdexisting position · 2,048,415 shares now+236,213
- Fidelity (FMR LLC)existing position · 4,017,344 shares now+210,099
- Arrowstreet Capital LPexisting position · 3,074,773 shares now+208,318
- Susquehanna International Group LLPexisting position · 181,129 shares now+111,018
Reductions
- Capital World Investorsexisting position · 7,278,038 shares now-993,118
- Wellington Management Group LLPexisting position · 855,093 shares now-863,153
- Renaissance Technologies LLCexisting position · 71,869 shares now-767,620
- T. Rowe Price Associates Incexisting position · 6,886,521 shares now-474,687
- Two Sigma Advisers LPexisting position · 462,820 shares now-453,380
New positions and exits
New (0)
No new position among listed positions.
Exited (3)
- Hudson Bay Capital Management LPwas $9.1m
- Quantbot Technologies LPwas $6.2m
- ExodusPoint Capital Management LPwas $2.6m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 23 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 21 | $5.0bn | n.a. | n.a. |
| Q4 2013 | 19 | $4.5bn | n.a. | n.a. |
| Q1 2014 | 18 | $4.2bn | n.a. | n.a. |
| Q2 2014 | 19 | $4.2bn | n.a. | n.a. |
| Q3 2014 | 18 | $5.1bn | n.a. | n.a. |
| Q4 2014 | 19 | $5.6bn | n.a. | n.a. |
| Q1 2015 | 22 | $5.8bn | n.a. | n.a. |
| Q2 2015 | 22 | $5.5bn | n.a. | n.a. |
| Q3 2015 | 25 | $5.2bn | n.a. | n.a. |
| Q4 2015 | 24 | $4.9bn | n.a. | n.a. |
| Q1 2016 | 26 | $5.4bn | n.a. | n.a. |
| Q2 2016 | 29 | $6.0bn | n.a. | n.a. |
| Q3 2016 | 27 | $5.8bn | n.a. | n.a. |
| Q4 2016 | 30 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 30 | $6.4bn | n.a. | n.a. |
| Q2 2017 | 35 | $7.0bn | n.a. | n.a. |
| Q3 2017 | 31 | $7.7bn | n.a. | n.a. |
| Q4 2017 | 30 | $7.8bn | n.a. | n.a. |
| Q1 2018 | 33 | $8.8bn | n.a. | n.a. |
| Q2 2018 | 32 | $9.9bn | n.a. | n.a. |
| Q3 2018 | 30 | $10.5bn | n.a. | n.a. |
| Q4 2018 | 27 | $12.4bn | n.a. | n.a. |
| Q1 2019 | 31 | $12.0bn | n.a. | n.a. |
| Q2 2019 | 28 | $14.6bn | n.a. | n.a. |
| Q3 2019 | 29 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 28 | $15.3bn | n.a. | n.a. |
| Q1 2020 | 32 | $13.4bn | n.a. | n.a. |
| Q2 2020 | 32 | $12.2bn | n.a. | n.a. |
| Q3 2020 | 32 | $11.8bn | n.a. | n.a. |
| Q4 2020 | 26 | $11.4bn | n.a. | n.a. |
| Q1 2021 | 26 | $12.3bn | n.a. | n.a. |
| Q2 2021 | 26 | $12.8bn | n.a. | n.a. |
| Q3 2021 | 30 | $11.6bn | n.a. | n.a. |
| Q4 2021 | 26 | $14.6bn | n.a. | n.a. |
| Q1 2022 | 32 | $15.8bn | n.a. | n.a. |
| Q2 2022 | 37 | $13.4bn | n.a. | n.a. |
| Q3 2022 | 38 | $10.9bn | n.a. | n.a. |
| Q4 2022 | 36 | $9.1bn | n.a. | n.a. |
| Q1 2023 | 32 | $9.6bn | n.a. | n.a. |
| Q2 2023 | 34 | $9.5bn | n.a. | n.a. |
| Q3 2023 | 33 | $9.8bn | n.a. | n.a. |
| Q4 2023 | 32 | $10.2bn | 18 | 14 |
| Q1 2024 | 30 | $8.9bn | 13 | 16 |
| Q2 2024 | 33 | $8.3bn | 20 | 11 |
| Q3 2024 | 35 | $10.0bn | 22 | 12 |
| Q4 2024 | 35 | $11.1bn | 16 | 15 |
| Q1 2025 | 35 | $12.1bn | 21 | 13 |
| Q2 2025 | 37 | $12.7bn | 18 | 17 |
| Q3 2025 | 33 | $11.9bn | 14 | 17 |
| Q4 2025 | 31 | $11.1bn | 20 | 26 |
| Q1 2026 | 33 | $11.4bn | 15 | 26 |
| Q2 2026 | 37 | $9.3bn | 31 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CME and V →CME and AXP →CME and BAC →Choose a stock to compare with CME →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CME, latest filings →Back to the 13F Explorer →